Ramipril Capsule
Product Images NDC 51655-347

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 51655-347). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655 347 52 Master Bottle Label Approval Rev A 10 20

51655 347 52 Master Bottle Label Approval   Rev A 10 20
This is a description of Ramipril Capsules; a prescription medication used for treating high blood pressure and heart failure. Each capsule contains 2.5 mg of ramipril. It is manufactured by Lupin Pharmaceuticals, Inc. and repackaged by Northwind Pharmaceuticals. These capsules come in a package of 30 and must be stored in the original container at temperatures ranging from 68°F-77°F. The dosage instructions are provided on the package insert, and it should be kept out of reach from children. Non-English text and some unreadable characters are also present in the text.*
FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 01

FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 02

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 02
The text is showing a graph with the proportion of patients taking a placebo or Ramipril over a period of "Days of Follow-up". The y-axis is labeled "Proportion of Patients" and the x-axis shows the number of days. The Ramipril group shows a significant increase in proportion of patients compared to the placebo group, as indicated by the p-value of 0.0001.*
FDA Label Image

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 03

9fb6ade9 C326 4291 A3d4 Dfc2502c29ab 03
This text provides information on the incidence of composite outcome in a study comparing a placebo group and a ramipril group. The data is further segmented based on factors such as cardiovascular disease, diabetes, age, sex, hypertension, and prior medical history. The relative risk in the ramipril group is also provided with a confidence interval.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.